| Baseline Characteristic |
No. of Patients |
% |
| Age |
| ≤50 |
57 |
43 |
| >50 |
73 |
56 |
| Tumor phenotype |
| Luminal A |
30 |
23 |
| Luminal B |
34 |
26 |
| Luminal B like |
26 |
20 |
| Her2 neu positive |
21 |
16 |
| Triple negative |
19 |
15 |
| Histology |
| Ductal |
117 |
90 |
| Lobular |
9 |
7 |
| Other |
4 |
3 |
| Grade |
| 1 |
0 |
|
| 2 |
18 |
14 |
| 3 |
112 |
86 |
| Proliferation index |
| Ki 67% ≤ 14% |
16 |
12 |
| Ki 67% ≥ 14% |
114 |
87 |
| Stage at initial breast cancer diagnosis |
| Stage I |
0 |
|
| Stage II |
21 |
16 |
| Stage III |
46 |
35 |
| Sage IV |
63 |
49 |
| Indications for PET/CT |
| Other abnormal radiology |
65 |
50 |
| Locally advanced breast cancer |
23 |
18 |
| Symptoms |
32 |
25 |
| Indication not determined |
10 |
7 |
| First therapy for MBC |
| Endocrine therapy |
31 |
24 |
| Targeted with or without endocrine therapy |
25 |
19 |
| Chemotherapy |
74 |
57 |
|
